Entrada Therapeutics, Inc. (TRDA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $14.45 (+7.04%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 28, 2026 | Kostas Biliouris | Oppenheimer | $21.00 | +45.3% |
| Nov 6, 2024 | Boobalan Pachaiyappan | H.C. Wainwright | $20.00 | +38.4% |
| Jun 25, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | +24.6% |
Top Analysts Covering TRDA
TRDA vs Sector & Market
| Metric | TRDA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +24.6% | +1150.2% | +14.9% |
| P/E Ratio | -3.71 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $11M | $22M | $36M | 6 |
| 2027-03-31 | $16M | $16M | $16M | 3 |
| 2027-06-30 | $5M | $5M | $5M | 2 |
| 2027-09-30 | $5M | $5M | $5M | 2 |
| 2027-12-31 | $5M | $5M | $5M | 3 |
| 2028-03-31 | $6M | $6M | $6M | 2 |
| 2028-06-30 | $6M | $6M | $6M | 1 |
| 2028-09-30 | $6M | $6M | $6M | 1 |
| 2028-12-31 | $6M | $6M | $6M | 2 |
| 2029-12-31 | $53M | $90M | $132M | 5 |
| 2030-12-31 | $148M | $249M | $367M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-4.24 | $-3.98 | $-3.27 | 6 |
| 2027-03-31 | $-0.79 | $-0.79 | $-0.79 | 1 |
| 2027-06-30 | $-1.02 | $-1.02 | $-1.02 | 1 |
| 2027-09-30 | $-1.01 | $-1.01 | $-1.01 | 1 |
| 2027-12-31 | $-1.00 | $-1.00 | $-1.00 | 1 |
| 2028-03-31 | $-1.18 | $-1.18 | $-1.18 | 2 |
| 2028-06-30 | $-1.22 | $-1.22 | $-1.22 | 2 |
| 2028-09-30 | $-1.26 | $-1.26 | $-1.26 | 2 |
| 2028-12-31 | $-1.33 | $-1.33 | $-1.33 | 2 |
| 2029-12-31 | $-4.52 | $-2.80 | $-1.33 | 1 |
| 2030-12-31 | $-3.00 | $-1.86 | $-0.88 | 1 |
Frequently Asked Questions
What is the analyst consensus for TRDA?
The consensus among 2 analysts covering Entrada Therapeutics, Inc. (TRDA) is Buy with an average price target of $18.00.
What is the highest price target for TRDA?
The highest price target for TRDA is $21.00, set by Kostas Biliouris at Oppenheimer on 2026-01-28.
What is the lowest price target for TRDA?
The lowest price target for TRDA is $18.00, set by Raghuram Selvaraju at H.C. Wainwright on 2024-06-25.
How many analysts cover TRDA?
2 analysts have issued ratings for Entrada Therapeutics, Inc. in the past 12 months.
Is TRDA a buy or sell right now?
Based on 2 analyst ratings, TRDA has a consensus rating of Buy (2.00/5) with a +24.6% upside to the consensus target of $18.00.
What are the earnings estimates for TRDA?
Analysts estimate TRDA will report EPS of $-3.98 for the period ending 2026-12-31, with revenue estimated at $22M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.